Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

OBIO vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Captures Overall Composite Edge (36.8 SELL vs 41.1 SELL), While OBIO Leads 4–1 on Growth & Valuation Pillars

BOLD Overall Winner 6-Pillar Tally: OBIO 4 – 1 BOLD (1 Tie) Matrix Metrics: OBIO 3 – 5 BOLD

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality), while OBIO wins 4–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY).
  • Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both OBIO (41.1/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBIO vs BOLD
OBIO NASDAQ
Orchestra BioMed Holdings, Inc. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$6.58
-6.0% 1D
Market Cap $550.9M
TTM Revenue $31M
Forward P/E N/M
Beta / 30D Vol 1.18β · 88% Vol
Unified Composite Score
41.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 64.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.7% over 20 days), RSI 55
RSI-14: 54.9 · SMA20: $6.19 · SMA50: $6.01
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (OBIO 4 – 1 BOLD)

Columns: Metric · OBIO · BOLD
1. Valuation Multiples OBIO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 17.9x N/M
2. Growth & Scale OBIO
Revenue Growth (YoY) -89.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $31M N/A
Market Cap $550.9M $56.2M
3. Profitability & Quality BOLD
Gross Margin 99.6% N/A
Operating Margin -195.4% 0.0%
Net Profit Margin -182.5% 0.0%
Return on Equity (ROE) -182.3% -64.6%
4. Balance Sheet & Cash Flow OBIO
Cash Generation (TTM) -$64M -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage $9.0M Net Debt (4.72x D/E) $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBIO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 78.2% (21st %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBIO (3) vs BOLD (5)
Institutional Metric OBIO BOLD Criterion Row Edge
Market Capitalization
Scale
$550.9M $56.2M Larger Scale OBIO
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-89.4% +0.0% Higher Growth BOLD
Operating Margin (TTM)
Profitability
-195.4% 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
-182.5% 0.0% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
-182.3% -64.6% Higher ROE BOLD
52-Week Range Position
Momentum
72% ($3–$8) 62% ($1–$3) Stronger Trend OBIO
Beta / 30D Volatility
Risk Regime
1.18β · 88% Vol -0.08β · 28% Vol Lower Realized Risk BOLD
Unified Institutional Score
Composite Signal
41.1 / 100 (SELL) 36.8 / 100 (SELL) Higher Composite OBIO
Trailing 12M Revenue (USD)
Operating Scale
$31M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
99.6% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 17.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$64M ($9.0M Net Debt (4.72x D/E)) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBIO +25.21 pp
OBIO: +20.29% · BOLD: -4.92%
3M Horizon OBIO +42.58 pp
OBIO: +20.96% · BOLD: -21.62%
6M Horizon OBIO +0.96 pp
OBIO: +62.07% · BOLD: +61.11%
1Y Horizon BOLD +60.54 pp
OBIO: +41.2% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBIO vs BOLD. Trailing 12-month operating profitability (OBIO -195.4% vs BOLD 0.0%) and valuation multiples (OBIO N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OBIO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31M
Gross Margin99.6%
Op. Margin-195.4%
ROE / Fwd P/E-182.3% · N/M
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBIO CONSOLIDATION
36d in phase · OBV ACCUMULATION
Current IV 78.2%
IV Percentile 21st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact OBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $550.9M market capitalization and -195.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBIO vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) captures the overall head-to-head institutional edge over Orchestra BioMed Holdings, Inc. (OBIO) on higher Unified Composite conviction (36.8/100 SELL vs. 41.1/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality), while OBIO wins 4–1 across the 6-pillar growth and valuation breakdown. OBIO trades at $6.58 (N/M Forward P/E, -195.4% operating margin) versus BOLD at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While OBIO currently prints a higher short-term Unified Composite Score (41.1/100 SELL vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (5–3 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -195.4% operating margin) and revenue trajectory (+0.0% vs. -89.4% YoY). Defensive Composite Rating Caution: Although BOLD compares more favorably head-to-head, both OBIO (41.1/100 SELL) and BOLD (36.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: OBIO trades in a Markup technical trend (CONSOLIDATION options phase, RSI 54.9); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

OBIO leads the Growth & Scale pillar: OBIO posts -89.4% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (99.6% gross margin, -195.4% operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, OBIO generates $31M in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, OBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

OBIO screens cheaper on headline valuation multiples. OBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.9x EV/Revenue (unreported FCF margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBIO (-182.3% ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, OBIO carries 78.2% implied volatility (21st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.18β · 88% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.